3Ti Selected as “Main-Stage” Presenting Company at SEBIO 2007

Winner of SEBIO 2006 “Early-Stage Shootout” contest, selection timely given Series A financing effort currently underway

ATLANTA – Sept. 25, 2007 – Transfusion & Transplantation Technologies LLC (3Ti), developer of next generation automated blood analyzer technology for the pre-transfusion (immunohematology) diagnostics market, announced today that 3Ti has been selected as one of 12 “main-stage” life sciences companies to present at the Ninth Annual Southeastern BIO Investor Forum (SEBIO) in Pinehurst, N.C., Nov. 7-8.

“After winning last year’s SEBIO Early-Stage Shootout contest, all of us at 3Ti appreciate this latest honor. This honor is also timely given initiation of a Series A financing effort this month,” said Terry Walts, president and CEO of 3Ti. “We remain indebted to SEBIO for their continued support and compliment them for all they do to help promising life sciences companies in Southeastern U.S. become successful.”

The Southeastern BIO Investor Forum is the Southeast region’s premier life sciences venture capital conference, connecting emerging life science companies with potential investors in a forum that provides meaningful networking opportunities. Attracting more than 400 attendees, including investors from the Southeast and from around the world, SEBIO showcases emerging life sciences companies from Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and beyond each year. This year, of the over 60 life sciences companies applying to present at SEBIO, just 12 were selected as “main-stage” presenting companies and 12 selected for the “Early-Stage Shootout” contest.

About Transplantation & Transplantation Technologies, LLC
Founded in 2000 by two distinguished physician-scientists at Emory University, Transfusion & Transplantation Technologies LLC is a medical device company developing “next generation” fully-automated blood bank multianalyzer technology for the pre-transfusion (immunohematology) diagnostics market. In late 2006 the Company won the “Early Stage Company Shootout” competition at the prestigious SEBIO Investor Forum. 3Ti’s first product,
the *Aegis* blood analyzer is being designed to perform routine blood typing, antibody screening, cross-matching and certain other tests “faster, better and more efficiently” than competitive analyzers and/or manual testing today. In addition, it is anticipated that the *Aegis*’ technology based on flow cytometry and novel multifunctional flexible architecture will help automate certain manual blood assays that have not been automatable to date as well as certain new and emerging new tests and testing platforms. The company believes that its *Aegis* technology has the potential over time to become the *standard of care* in pre-transfusion (immunohematology) blood bank testing worldwide. For more information about Transfusion & Transplantation Technologies, contact David Doolittle or the company directly.

###

**Forward-Looking Statements**

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company’s technologies, possible future financings or other activities and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” “potential,” or similar expressions. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.